Open AccessPharmacodynamics of Meropenem against Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model
Author(s) -
Majid Sirati-Sabet,
Ziad Tarazi,
David C. Griffith
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02388-19
Subject(s) - meropenem , acinetobacter baumannii , pharmacodynamics , acinetobacter , microbiology and biotechnology , medicine , antibiotics , biology , pharmacology , pharmacokinetics , bacteria , pseudomonas aeruginosa , antibiotic resistance , genetics
Acinetobacter baumannii infections are difficult to treat and have limited treatment options. Carbapenems, including meropenem, are currently considered the first-line agents for the treatment of infections caused by Acinetobacter spp. The percentage of a 24-hour period that the concentration of free drug in plasma is above the MIC (%24-h f T>MIC) to achieve stasis, 1 log CFU, or 2 log CFU of bacterial killing against A. baumannii has not been studied previously for meropenem. The objective of this study was to determine these parameters for meropenem against A. baumannii in a neutropenic mouse thigh infection model. Six A. baumannii clinical isolates with MICs ranging from 0.25 to 16 mg/liter were tested. Meropenem produced a bacteriostatic effect with a %24-h f T>MIC of 7 to 24% and produced 1 log CFU of bacterial killing with a %24-h f T>MIC of 15 to 37%.